#PARDES BIOSCIENCES REGISTRATION#
These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, development of competing therapeutic treatments for COVID-19 on Pardes' business, results of nonclinical and early clinical studies may not be representative or predictive of the outcomes of on-going or future clinical studies, interim, "topline" and preliminary data from our clinical trial may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data, patient recruitment and enrollment in Pardes' clinical trials may be influenced by numerous factors, whether emergency use authorization pathway will be available, Pardes' ability to obtain and maintain intellectual property protection for Pardes' products and technologies, capital to finance our operations may not be available to us on acceptable terms, or at all, inflation may cause studies to cost more than projected, and the effect of the COVID-19 pandemic, including mitigation efforts, quarantines, vaccination rates, infection rates, treatment options, and the war in Ukraine, on any of the foregoing or other aspects of Pardes' business operations, and/or other risks and uncertainties, including those included under the header "Risk Factors" in the most recent registration statement on Form S-1 filed with the U.S. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "seek," "should," "target," "will," "would" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.įorward-looking statements in this presentation include, but are not limited to, statements about: the design, endpoints and timing of our Phase 2/3 study, the potential attributes and benefits of PBI-0451, including potential to achieve and maintain target blood levels anticipated to show clinical efficacy, potential to be preferred unboosted COVID-19 oral antiviral, adequate manufacturing capacity and capital to produce clinical trial material for our current anticipated clinical program.
All statements other than statements of historical facts contained in this presentation, including statements regarding the Pardes Biosciences Inc.'s ("Pardes") strategy, financial condition, clinical and development plans, manufacturing supplies, adequacy of capital and prescriber preferences are forward-looking statements. This presentation contains "forward-looking statements" and information that are based on beliefs, assumptions and information currently available and that are within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.
Cautionary Note Regarding Forward Looking Statements